Sarepta Therapeutics, Inc. (NASDAQ:SRPT) SVP Shamim Ruff sold 10,000 shares of Sarepta Therapeutics stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $55.00, for a total transaction of $550,000.00. Following the completion of the sale, the senior vice president now directly owns 37,045 shares in the company, valued at approximately $2,037,475. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Shamim Ruff also recently made the following trade(s):

  • On Tuesday, October 3rd, Shamim Ruff sold 11,500 shares of Sarepta Therapeutics stock. The shares were sold at an average price of $50.00, for a total transaction of $575,000.00.

Sarepta Therapeutics, Inc. (NASDAQ SRPT) opened at $54.16 on Friday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 9.52 and a current ratio of 10.44. Sarepta Therapeutics, Inc. has a 52-week low of $26.26 and a 52-week high of $57.57.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported ($0.20) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.66. The business had revenue of $45.95 million during the quarter, compared to analyst estimates of $41.29 million. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. During the same quarter in the previous year, the business posted ($0.95) earnings per share. research analysts forecast that Sarepta Therapeutics, Inc. will post -3.11 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/11/11/sarepta-therapeutics-inc-srpt-svp-sells-550000-00-in-stock.html.

Several large investors have recently bought and sold shares of the company. BlackRock Inc. raised its position in shares of Sarepta Therapeutics by 4,403.1% in the first quarter. BlackRock Inc. now owns 5,292,729 shares of the biotechnology company’s stock valued at $156,664,000 after buying an additional 5,175,193 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Sarepta Therapeutics by 4.0% in the second quarter. Vanguard Group Inc. now owns 4,259,029 shares of the biotechnology company’s stock valued at $143,572,000 after buying an additional 162,543 shares during the last quarter. State Street Corp raised its position in shares of Sarepta Therapeutics by 21.2% in the first quarter. State Street Corp now owns 3,197,127 shares of the biotechnology company’s stock valued at $94,641,000 after buying an additional 559,342 shares during the last quarter. HealthCor Management L.P. raised its position in shares of Sarepta Therapeutics by 31.1% in the second quarter. HealthCor Management L.P. now owns 2,031,890 shares of the biotechnology company’s stock valued at $68,495,000 after buying an additional 481,890 shares during the last quarter. Finally, Jennison Associates LLC raised its position in shares of Sarepta Therapeutics by 103.9% in the third quarter. Jennison Associates LLC now owns 1,143,853 shares of the biotechnology company’s stock valued at $51,885,000 after buying an additional 582,894 shares during the last quarter. 65.58% of the stock is owned by institutional investors and hedge funds.

Several brokerages have recently weighed in on SRPT. Credit Suisse Group reaffirmed an “outperform” rating and issued a $81.00 target price on shares of Sarepta Therapeutics in a report on Monday, October 2nd. Robert W. Baird reaffirmed a “buy” rating and issued a $101.00 target price on shares of Sarepta Therapeutics in a report on Tuesday, October 17th. William Blair reiterated an “outperform” rating on shares of Sarepta Therapeutics in a research note on Monday, October 2nd. Zacks Investment Research upgraded shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, August 2nd. Finally, Piper Jaffray Companies reiterated an “overweight” rating and issued a $55.00 price objective (up previously from $50.00) on shares of Sarepta Therapeutics in a research note on Thursday, September 7th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and sixteen have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $63.59.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.